Parvovirus B19: The Virus Behind Fifth Disease

A child arrives at school with rosy, slapped-looking cheeks and seems perfectly fine. A week or two earlier, while the child had little more than a mild cold, the virus was moving through the classroom. By the time the distinctive rash appears, the contagious window has usually closed. That is the quiet trick of Parvovirus B19, the pathogen behind erythema infectiosum, better known as fifth disease, and it explains why the same virus is harmless to most people and dangerous to a few.

Educational content, not medical advice. Talk to your doctor before changing any medication, treatment, or routine. Information here reflects current research but every person's situation differs.

Understanding this virus matters far beyond pediatric clinics. The pathogen that causes a mild rash in a healthy child can trigger a severe drop in red blood cells in someone with sickle cell disease, a long-lasting anemia in someone with a weakened immune system, or fetal anemia and heart strain in a pregnancy. This article walks through the biology that connects those outcomes: how the virus gets into cells, why it targets one cell lineage, how the illness unfolds, and what clinicians do about it.

What is Parvovirus B19?

Parvovirus B19 is one of the smallest viruses known to infect humans. Its genome is a single strand of DNA about 5,600 nucleotides long (5,596 in the reference description), packaged inside a non-enveloped, icosahedral protein shell roughly 22 to 24 nanometers across. A nanometer is a billionth of a meter, so about 40,000 of these particles laid side by side would span a millimeter.

Taxonomically, it belongs to the family Parvoviridae. The genus is now called Erythroparvovirus, though older papers use Erythrovirus. The family name comes from the Latin parvum, meaning small. Three genotypes are recognized.

The "B19" in the name is a laboratory accident preserved in print. In 1975, the Australian virologist Yvonne Cossart was screening donor blood for hepatitis B, and one sample, number 19 in panel B, gave an anomalous result. Under the electron microscope it turned out to hold particles that looked like a parvovirus. The sample code stuck as the virus's name.

The disease link came later. Only in the early 1980s was the virus tied to fifth disease itself. Earlier, the virus had been linked to sudden collapses in red cell production in people with chronic hemolytic anemias, a pattern clinicians called aplastic crisis.

Why being "naked" matters

Many familiar viruses, such as influenza and SARS-CoV-2, wear an outer lipid membrane. Soap and alcohol-based products break that membrane apart, and that is a large part of why hand washing works. Parvovirus B19 has no such envelope. A naked protein shell is generally harder to inactivate with alcohol-based products, which is one reason careful hand washing with soap and water is the standard advice. Even so, hygiene only helps so much against a virus that spreads before anyone knows they are sick.

The tight, rigid capsid also limits how much genetic material the virus can carry. That is the reason B19 depends heavily on the host cell's machinery, and the reason it picks cells that are busy copying DNA.

The P antigen: why B19 has such a narrow target

Most viruses can enter several cell types. B19 is unusual for its selectivity. Its main receptor is the P antigen, also called globoside, a glycolipid (a fat molecule carrying a sugar chain) that sits on the surface of certain cells. Think of the P antigen as the lock and the virus as a key that fits almost nowhere else. The cells that carry the most P antigen, and that the virus can then use, are the erythroid progenitors in bone marrow. These are the dividing cells that mature into red blood cells.

This one fact explains most of B19's biology:

• It replicates mainly in red blood cell precursors, not in mature red blood cells.
• It needs actively dividing cells, so the rapidly multiplying precursors are ideal hosts.
• About 1 in 200,000 people lack the P antigen, according to a standard review, and they are naturally resistant to infection.

The P antigen belongs to a family of blood group antigens, so its story overlaps with the one told in the article on ABO and Rh blood types. Most of us carry it and never notice, because it has no effect until a virus tries to use it.

A factory that stops for a week

Picture red blood cell production as an assembly line. Precursors in the bone marrow mature into reticulocytes (young red cells), which are released into the blood. A mature red blood cell lasts about 120 days, so a healthy body has a very large stockpile in circulation.

When B19 infects the precursors, the line stops. In a healthy person, a pause of a week or so is invisible, because the stockpile covers the gap. In a person whose red cells are destroyed much faster than normal, such as someone with sickle cell disease, hereditary spherocytosis, or thalassemia, there is no stockpile to draw on. The same short pause becomes a crisis. This is the point where a harmless childhood virus becomes an emergency.

If you want the basics of how viruses use host cells, the explainer on how viruses work from infection to replication covers the general mechanism. For where red blood cells come from, see the overview of how blood works.

How it spreads and who has had it

B19 spreads mainly through respiratory droplets from the nose and throat of an infected person. It can also pass through blood and blood products, and from a pregnant person to the fetus across the placenta.

Contact matters a great deal. A standard review reports an attack rate of about 50% in susceptible children in household and school settings, and 20% to 30% in susceptible teachers. That fits the way the virus spreads: close, prolonged exposure in homes, schools, and daycare centers.

Infection in childhood leaves lasting antibodies, so immunity builds up with age. The table below summarizes seroprevalence (the share of people with IgG antibodies, a sign of past infection) from a standard review.

Age group	Share with past infection (IgG)
Children 1 to 5 years	2% to 15%
Children 6 to 19 years	15% to 60%
Adults	30% to 60%
Older adults	Above 85%

Source: Heegaard and Brown, Clinical Microbiology Reviews, 2002.

In other words, roughly a third to a half or more of adults have been infected at some point. The rest are the group for whom exposure carries risk, and it includes pregnant people who have never been exposed.

The 2024 surge

Activity has not been steady. In August 2024, the CDC issued a health advisory telling clinicians to watch for B19 as cases rose in the United States, with most infections among children ages 5 to 9. According to reporting at the time, the European Centre for Disease Prevention and Control said the virus had been circulating at unusually high rates in Europe since March of that year. Pediatricians quoted in that coverage described seeing in a week what they usually saw in a month. The advisory singled out pregnant people and people with sickle cell disease who had never been exposed as being at risk of serious illness.

The paradox of the pre-rash contagion

Here is the feature that frustrates infection control. People with fifth disease are generally infectious before symptoms appear and probably not after the characteristic rash arrives. The rash is not a sign of active viral spread. It reflects the immune system clearing the virus, and it follows the infectious phase.

That means keeping a child with the rash out of school achieves little, because the people most likely to have spread the virus never showed the rash. Local health authorities set their own rules, but the biology explains why many do not exclude children for the rash alone.

The illness in two acts

Fifth disease in healthy people tends to follow a two-phase pattern, with an apparent recovery in between. In volunteer studies summarized in the same review, the facial rash began about 18 days after infection, with the body rash following one to four days later.

Act one: the viremic phase

In the first phase, the virus multiplies in the bone marrow and enters the bloodstream (viremia). Symptoms, when present, are nonspecific: fever, headache, muscle aches, a runny nose, a sore throat. Many people think they have a cold. About 1 in 4 infected people have no symptoms at all, according to the CDC.

Behind the scenes, red cell production slows. Reticulocyte counts drop and hemoglobin dips slightly, which a healthy person does not feel. The immune system then produces IgM antibodies, followed by IgG, that neutralize the virus and clear the viremia.

Act two: the immune rash

A few days after the fever or flu-like symptoms, the immune response produces the signature rash:

• Face: Bright red cheeks, often described as slapped, with relative paleness around the mouth. The skin may feel warm.
• Body: A lacy or net-like rash on the trunk, arms, and thighs that can be itchy. The pattern comes from central clearing as individual patches fade.
• Course: According to the CDC, the rash usually clears in 7 to 10 days but can come and go for several weeks, often returning with heat, exercise, or sun exposure.

The rash is the product of immune complexes, which are clumps of antibody and viral fragments that inflame the skin. It is the immune system's cleanup, not the virus's attack.

Who gets what: how the same virus behaves in different hosts

The virus is identical in each of the cases below. What changes is the host's immune status and red blood cell physiology.

Healthy children

Classic fifth disease, mild and self-limiting. Joint symptoms occur in roughly 10% of children or fewer, according to the Heegaard and Brown review. Treatment is supportive, aimed at relieving symptoms.

Adults, especially women

Adults often skip the rash and develop joint symptoms instead. The same review reports arthralgia or arthritis in about 60% of women and 30% of men with infection. The CDC describes pain and swelling (polyarthropathy syndrome) on both sides of the body, usually in the hands, feet, and knees, most common in women. It usually lasts one to three weeks but can last months or longer, and it usually resolves without long-term problems.

In a minority, the joint disease lingers. The review notes that about half of people with chronic B19-related arthropathy meet the criteria for rheumatoid arthritis, so the two can be confused. This is one reason atypical joint complaints deserve proper testing and not guesswork.

Sickle cell disease and other hemolytic anemias

This is the most urgent presentation. People with sickle cell disease, thalassemia, or hereditary spherocytosis make red blood cells at a punishing pace because their cells die early. When B19 halts production, the effect is called transient aplastic crisis: a sudden, severe fall in red blood cell count.

The review reports that B19 accounts for 70% to 80% of aplastic episodes in people predisposed to them, and that the crisis usually resolves within about two weeks once antibodies appear. Because the patient's hemoglobin can fall quickly, treatment is supportive care and blood transfusion while the immune system catches up. The CDC's 2024 advisory named people with sickle cell disease who have never been exposed as being at risk of serious illness, so anyone with the condition should contact their care team after an exposure.

A treadmill is a useful picture here. A healthy person walks on it at a leisurely speed and can pause without consequences. A person with sickle cell disease is on a sprint setting, and if the belt stops, they fall at once.

Immunocompromised people

In people with HIV, organ transplants, certain cancers, or immunosuppressive treatments, the immune system may not make a strong enough antibody response to clear the virus. The infection becomes chronic, and the bone marrow keeps being suppressed. The result can be pure red cell aplasia, a long-lasting anemia that may require repeated transfusions.

Intravenous immunoglobulin (IVIG), a preparation of pooled donor antibodies, is the established treatment. The review describes it as often ameliorative and sometimes curative. Relapse can happen if the underlying immune suppression continues. There is no licensed antiviral drug that targets B19 specifically.

Pregnancy: why timing matters

B19 can cross the placenta and infect the fetus's red cell precursors. The fetal immune system is immature and the fetal red cell mass is expanding rapidly, so there is little reserve. Severe fetal anemia can lead to heart failure and a buildup of fluid in the fetus called hydrops fetalis, which includes swelling under the skin and fluid in the abdomen, chest, and around the heart.

The numbers, from a standard review, put the risk in proportion:

Measure	Reported figure
Primary maternal infection in pregnancy	About 1% to 5%
Transmission to the fetus	24% to 33%
Abnormal outcome after confirmed primary infection	About 5% to 10%
Hydrops in recent studies	About 1% to 1.6%
Highest-risk window	11 to 23 weeks of pregnancy
Share of nonimmune hydrops attributed to B19	15% to 20%

Hydrops is serious. The review reports a case fatality of about 50% in hydropic fetuses, falling to 18% with transfusion. Another line of evidence is more recent. A more recent two-center retrospective study of 103 fetuses that received intrauterine transfusion between 2002 and 2021 reported 84.5% survival overall (Archives of Gynecology and Obstetrics), with hydrops strongly linked to fetal death.

The CDC's current wording is deliberately measured. It says infection early in pregnancy can slightly increase the risk of miscarriage, and that spread to the baby is not common. The two statements fit together. Most infections in pregnancy end without harm, but because a minority do not, and because the outcome is so serious when it goes wrong, clinicians watch exposed pregnant people closely.

How clinicians monitor a pregnancy

A pregnant person who has been exposed to someone with the infection is usually tested for IgG and IgM antibodies. A positive IgG and negative IgM suggests past infection and immunity, which protects the fetus. A positive IgM suggests recent infection, and viral DNA testing by PCR can confirm it.

If infection is confirmed, ultrasound surveillance looks for signs of fetal anemia. A key tool is middle cerebral artery peak systolic velocity (MCA-PSV), a Doppler measurement of blood flow speed in a fetal brain artery. Anemic blood is thinner and flows faster, so a velocity that rises above the expected range for gestational age is a warning sign. If anemia is severe, the fetus can be given red blood cells directly through an intrauterine transfusion.

Guidelines on testing intervals differ between health systems, so a pregnant person should follow the advice of their own obstetric team. No vaccine prevents B19 infection.

Diagnosis

In the classic childhood presentation, the diagnosis is clinical, based on the rash and the setting. Laboratory tests become essential in atypical cases.

Test	When it is used	What it shows
IgM antibodies	Acute infection in people with working immune systems	More than 85% of people with fifth disease or aplastic crisis are IgM-positive; IgM persists for 2 to 3 months
IgG antibodies	Checking immunity, especially in pregnancy	Past infection, usually protective
PCR for viral DNA	Immunocompromised patients, aplastic crisis, fetal diagnosis	Detects the virus directly when antibodies are absent or unreliable
Reticulocyte count	Aplastic crisis	Very low counts signal that red cell production has stopped
Fetal ultrasound with MCA Doppler	Pregnancy surveillance	Detects fetal anemia noninvasively

One caution applies to PCR. Low levels of viral DNA can persist for a long time after infection, so a positive PCR result alone does not prove the infection is recent. Clinicians read it together with antibody results and symptoms.

How fifth disease compares with other childhood rashes

The name "fifth disease" reflects a historical numbering of childhood rash illnesses, in which erythema infectiosum ranked fifth among the pink-red rashes that physicians described. The label stuck even though the numbering scheme was abandoned.

Disease	Cause	Rash	Contagious with rash?	Vaccine
Fifth disease	Parvovirus B19 (DNA virus)	Slapped cheeks, lacy body rash	Usually no	None
Measles	Measles virus (RNA virus)	Spreading blotchy rash from head down	Yes	Yes (MMR)
Rubella	Rubella virus (RNA virus)	Pink, finely spotted rash	Yes	Yes (MMR)
Roseola	Human herpesvirus 6 or 7	Pink rash on the trunk after fever ends	No, rash follows the fever	None
Chickenpox	Varicella-zoster virus	Itchy blisters	Yes, until crusted	Yes
Scarlet fever	Group A Streptococcus	Sandpaper-textured rash	Yes, until treated	None

For related illnesses, see the coverage of rubella virus and congenital rubella syndrome, measles virus, herpesviruses, and shingles and varicella-zoster virus. Roseola is caused by two of the human herpesviruses, so the herpesvirus article is the closest match.

The comparison highlights something about B19's timeline. Measles and chickenpox are most contagious around the time the rash appears, which makes isolation useful. Fifth disease reverses that logic.

Treatment, prevention, and the vaccine gap

For healthy children and adults, B19 infection usually resolves on its own. The CDC says treatment mainly relieves symptoms such as fever, itching, joint pain, and swelling, and that people with a low blood count may need supportive care, blood products, or other specialized therapies.

There are three main clinical tools for the high-risk groups:

• Blood transfusion for severe anemia during an aplastic crisis.
• IVIG for chronic infection in people who cannot clear the virus.
• Intrauterine transfusion for severe fetal anemia.

No vaccine is licensed. A candidate made of empty capsid shells (virus-like particles built from the VP1 and VP2 proteins) was developed, and early trials were promising. According to a reference overview, a Phase I trial was halted because of unexplained reactions in some participants, and as of 2020 no vaccine had been approved. The problem is not that the target is unclear. It is that a vaccine would be aimed at a small group of high-risk people, which makes the safety and cost calculation harder.

Prevention therefore rests on everyday hygiene: washing hands, covering coughs, and not sharing cups and utensils. Given the pre-rash contagion, none of this is a guarantee, and it is most worth the effort around people at high risk. For a deeper look at how antibodies and immunity work, the explainers on antibody structure and the immune system are a good next step.

What people get wrong about fifth disease

"The rash means my child is contagious." The reverse is usually true. The rash appears after the infectious phase.

"It is only a children's illness." Adults get it too, often as joint pain without a rash, and adults are the ones more likely to have lingering joint symptoms.

"It is dangerous for everyone." For most healthy people it is a mild illness, and about a quarter of infected people have no symptoms at all. The danger is concentrated in a small number of groups defined by their blood or immune physiology.

"If you are pregnant and exposed, the baby will be harmed." Most exposures and most infections end without harm. The risk is real but small, and it is concentrated in the first half of pregnancy, with the highest-risk window reported at 11 to 23 weeks.

"Dog parvovirus and human parvovirus are the same." They are different viruses in the same family. Canine parvovirus does not cause fifth disease in people, and B19 does not infect dogs.

Frequently asked questions

Q: Can you get fifth disease more than once? A: In healthy people, infection usually leaves lasting IgG antibodies, and repeat infection is considered rare. People who cannot mount an adequate antibody response, such as some immunocompromised patients, can have persistent or recurrent infection. Adults who never had the infection as children can catch it for the first time later in life.

Q: Is fifth disease dangerous in pregnancy? A: It can be, but most infections do not harm the baby. A standard review reports abnormal outcomes in about 5% to 10% of confirmed primary infections, with the highest risk between 11 and 23 weeks. Severe fetal anemia can be treated with intrauterine transfusion. A pregnant person who has been exposed should contact their obstetric provider promptly and not wait for symptoms.

Q: Why is it called fifth disease? A: The name comes from a historical numbering of childhood rash illnesses, in which erythema infectiosum ranked fifth. The label stuck even though the numbering scheme was abandoned.

Q: How long is a person contagious? A: People are generally infectious before symptoms appear and probably not after the characteristic rash arrives. The infectious window is therefore mostly over by the time the illness is recognized. People with aplastic crisis or chronic infection can be highly viremic, and they are handled differently by clinicians.

Q: Why does parvovirus B19 only affect red blood cell precursors? A: The virus uses the P antigen (globoside) as its main receptor, and it replicates in dividing cells. Red blood cell precursors in the bone marrow carry the receptor and divide rapidly, so they are the main target. People who lack the P antigen, about 1 in 200,000, are resistant.

Q: What happens when someone with sickle cell disease gets B19? A: They can develop a transient aplastic crisis, in which red cell production stops while their cells continue to be destroyed. The anemia can become severe within days. Treatment is supportive, often with blood transfusion, and the crisis usually resolves within about two weeks once antibodies appear. Because the CDC's 2024 advisory named people with sickle cell disease as at risk, they should contact their care team after exposure or if symptoms appear.

Q: Is there a vaccine for parvovirus B19? A: No vaccine is licensed. A virus-like-particle candidate reached early human trials, but according to a reference overview a Phase I trial was stopped because of unexplained reactions, and as of 2020 no vaccine had been approved. Prevention relies on hygiene and awareness of the pre-rash contagious period.

The takeaway

Parvovirus B19 shows how a single molecular detail can set the whole shape of a disease. One receptor, the P antigen, restricts the virus to the cells that become red blood cells, and that restriction explains why the illness is trivial in a child, painful in an adult's joints, dangerous when red cells are already in short supply, and threatening to a fetus whose marrow is still being built. It also explains the odd timing: the rash is the immune system's cleanup, and it arrives after the contagious period is already over. The practical lesson for readers is to treat the rash as a clue to what has already happened, and to take exposure seriously only for the few groups whose biology makes a week of paused red cell production costly.

Sources and further reading

1. Heegaard ED, Brown KE. "Human parvovirus B19." Clinical Microbiology Reviews. 2002;15(3):485-505. Full text.
2. Centers for Disease Control and Prevention. About parvovirus B19.
3. NBC News. CDC health advisory on rising parvovirus B19 activity, August 14, 2024.
4. Wikipedia. Parvovirus B19, used for genotypes, discovery history, and vaccine status.
5. Young NS, Brown KE. "Parvovirus B19." New England Journal of Medicine. 2004;350(6):586-597.
6. Cossart YE, et al. "Parvovirus-like particles in human sera." Lancet. 1975;1(7898):72-73.
7. Intrauterine transfusion in 103 fetuses with severe anemia caused by parvovirus infection: a multicenter retrospective study. Archives of Gynecology and Obstetrics, 2023 (PMID 35916962).

---

Read next:

• Adenovirus Explained: The Hardy Virus Behind Many Diseases
• BK Virus, JC Virus & Polyomaviruses Explained
• Seasonal Coronaviruses: OC43, 229E, NL63 & HKU1